Edition:
United States

Mersana Therapeutics Inc (MRSN.OQ)

MRSN.OQ on NASDAQ Stock Exchange Global Select Market

15.81USD
8 Dec 2017
Change (% chg)

$-0.19 (-1.19%)
Prev Close
$16.00
Open
$15.92
Day's High
$15.99
Day's Low
$15.70
Volume
4,666
Avg. Vol
17,498
52-wk High
$21.01
52-wk Low
$12.75

Chart for

About

Mersana Therapeutics, Inc. is a United States-based biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs). The Company focuses on advancing a pipeline of targeted oncology therapeutics leveraging its Fleximer immunoconjugate technology. The Fleximer platform allows it to design... (more)

Overall

Beta: --
Market Cap(Mil.): $359.73
Shares Outstanding(Mil.): 22.75
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 186.11 15.67
EPS (TTM): -- -- --
ROI: -- -11.32 34.62
ROE: -- -35.69 16.00

BRIEF-Mersana announces third quarter loss of $0.35 per share

* Mersana announces third quarter 2017 financial results and provides business updates

Nov 09 2017

BRIEF-Mersana announces FDA clearance of IND application for XMT-1536

* Mersana announces FDA clearance of IND application for XMT-1536, a first-in-class antibody drug conjugate targeting NaPi2b

Oct 30 2017

BRIEF-Mersana Therapeutics increases size of board and appoints Lawrence Alleva as class III director‍​

* Mersana Therapeutics Inc - Increased size of the board from six to seven directors and appointed Lawrence M. Alleva to serve as a class III director‍​ Source text: (http://bit.ly/2j4r2t3) Further company coverage:

Sep 06 2017

BRIEF-Mersana Q2 loss per share $6.33

* Mersana announces second quarter 2017 financial results and provides business updates

Aug 11 2017

BRIEF-Mersana Therapeutics says Pfizer reports 9.8 percent passive stake in Mersana as of July 3 - SEC Filing

* Pfizer Inc. reports 9.8 percent passive stake in Mersana Therapeutics Inc as of July 3 - sec filing Source text for Eikon: Further company coverage:

Jul 13 2017

BRIEF-Rock Springs Capital Management reports 6.8 pct passive stake in Mersana Therapeutics as of June 28, 2017

* Rock Springs Capital Management LP reports a 6.8 percent passive stake in Mersana Therapeutics Inc as of June 28, 2017 - sec filing Source text (http://bit.ly/2uTwTCc) Further company coverage:

Jul 07 2017

BRIEF-Mersana Therapeutics announces pricing of initial public offering

* Mersana Therapeutics announces pricing of initial public offering

Jun 27 2017

BRIEF-Mersana Therapeutics sees IPO of 5 mln shares priced between $14 and $16

* Mersana Therapeutics Inc sees IPO of 5 million shares priced between between $14.00 and $16.00 - SEC filing Source text for Eikon: Further company coverage:

Jun 16 2017

Earnings vs. Estimates